Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001;322:716-720.
American College of Cardiology. ASCVD Risk Calculator Plus. http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/. Accessed July 27, 2018.
MESA Risk Calculator.https://www.mesa-nhlbi.org/CAC-Tools.aspx. Accessed July 27, 2018.
Naito R, Miyauchi K, Daida H. Racial differences in the cholesterol-lowering effect of statin. J Atheroscler Thromb. 2017;24:19-25.
Kenny PJ. Reward mechanisms in obesity: new insights and future directions. Neuron. 2011;69:664-679.
Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Future Cardiol. 2005;1:39-59.
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735-742.
Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K, et al. Effect of pitavastatin on glucose, HbA_1c and incident diabetes: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis. 2015;241:409-418.
Stone NJ, Robinson JG, Lichtenstein AH, et al. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med. 2014;160:339-343.
Taguchi I, Iimuro S, Iwata H, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. Circulation. 2018;137:1997-2009.
ClinicalTrials.gov. Dyslipidemia of obesity intervention in teens (DO-IT). https://clinicaltrials.gov/ct2/show/NCT02956590. Accessed July 27, 2018.
ClinicalTrials.gov. Effects of pitavastatin on insulin sensitivity and liver fat. https://clinicaltrials.gov/ct2/show/NCT02290106?term=effects+of+pitavastatin&rank=1. Accessed July 27, 2018.
Jordan LM. Self-management goals made simple (excerpts from 2014 PCMH pre-conference). https://www.jointcommission.org/assets/1/18/presentation_ahc_pcmh_joint_commission_2014_pcmh_pre-conf-patient_self-management.pdf. Accessed July 27, 2018.

CME / ABIM MOC / CE

Obesity and Dyslipidemia: How Would You Treat?

Authors: Harold Bays MD; Chima Nwizu MD; Adina S. Gutstein, MSN, CRNP, CLS
CME / ABIM MOC / CE Released: 8/20/2018
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 8/20/2019, 11:59 PM EST

Target Audience and Goal Statement

This activity is intended for primary care physicians, diabetologists & endocrinologists, cardiologists, nurses, NP's, and pharmacists.

The goal of this activity is to improve clinicians' ability to optimally manage lipid-lowering therapies in patients with metabolic syndrome and obesity.

Upon completion of this activity, participants will:

Have greater competence related to
- Application of effective lipid-lowering therapies in patients with metabolic syndrome and obesity
- Tailoring statin therapy in patients with obesity and dyslipidemia to minimize cardiovascular disease (CVD) risk
- Use of appropriate statin therapy in patients with obesity to minimize the effect on glucose metabolism and new onset diabetes

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Harold Bays, MD

Medical Director
Louisville Metabolic and Atherosclerosis Research Center
Louisville, Kentucky

Disclosures

Disclosure: Harold Bays, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Aegerion; Amarin Corporation plc; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; ChromaDex; Esperion Therapeutics, Inc.; Gemphire; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Kowa Company Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Prosciento; Regeneron Pharmaceuticals, Inc.; Sanofi
Served as a speaker or a member of a speakers bureau for: Amarin Corporation plc; Amgen Inc.; Kowa Company Ltd.; Regeneron Pharmaceuticals, Inc.; Sanofi.
Received grants for clinical research from: Acasti; Alere; Allergan, Inc.; Amarin Corporation plc; Amgen Inc.; Arena Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; ChromaDex; Dr. Reddy; Eisai Inc.; Esperion Therapeutics, Inc.; Ferrer/Chiltern; Gan and Lee; Gemphire; Gilead Sciences, Inc.; GlaxoSmithKline; Home Access; iSpecimen; Ionis; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; LIB Therapeutics; MedImmune Inc.; Merck & Co., Inc.; Necktar; Nichi-Iko; Novartis Pharmaceuticals Corporation; Novo Nordisk; Omthera; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Selecta; Takeda Pharmaceuticals North America, Inc.

Dr Bays does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Bays does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

Chima Nwizu, MD

Clinical Lipidologist
Diplomate
American Board of Obesity Medicine
Diplomate
American Board of Clinical Lipidology
Greeley, Colorado

Disclosures

Disclosure: Chima Nwizu, MD, has disclosed no relevant financial relationships.

Dr Nwizu does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Nwizu does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Adina S Gutstein, MSN, CRNP, CLS

Nurse Practitioner
Diplomate
Accreditation Council for Clinical Lipidology
Preventive Cardiology and Risk Factor Management
Philadelphia, Pennsylvania

Disclosures

Disclosure: Adina S. Gutstein, MSN, CRNP, CLS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
Served as a speaker or a member of a speakers bureau for: Amarin Corporation plc; Regeneron Pharmaceuticals, Inc.; Sanofi
Owns stock, stock options, or bonds from: Merck & Co., Inc.; Walgreens

Ms Gutstein does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Ms Gutstein does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Steering Committee

Chair

Alan S. Brown, MD

Affiliation: Director, Advocate Heart Institute, Advocate Lutheran General Hospital, Park Ridge, Illinois

Disclosures

Disclosure: Alan S. Brown, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Akcea Therapeutics; Amgen Inc.; Kastle Therapeutics; Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Kowa Company Ltd.; Regeneron Pharmaceuticals, Inc.; Sanofi

Members

Harold Bays, MD

Medical Director, Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky

Disclosures

Disclosure: As listed above.

Joseph L. Lillo, DO

Assistant Professor, Family Medicine, Midwestern University College of Osteopathic Medicine, Glendale, Arizona, United States

Disclosures

Disclosure: Joseph L. Lillo, DO, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Amarin Corporation plc; Amgen Inc.; Kowa Company Ltd.; Sanofi

Kevin C. Maki, PhD

Chief Scientist, Midwest Biomedical Research, Wheaton, Illinois, United States

Disclosures

Disclosure: Kevin C. Maki, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Akcea Therapeutics; Amgen Inc.; Kowa Company Ltd.; Regeneron Pharmaceuticals, Inc.; Sancilio & Company, Inc.

Kausik Ray, MBChB, MD, MPhil (Cantab), FRCP (Lon), FRCP (Ed)

Professor of Public Health, Imperial College London, London, United Kingdom

Disclosures

Disclosure: Kausik Ray, MBChB, MD, MPhil (Cantab), FRCP (Lon), FRCP (Ed), has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Cerenis Therapeutics; Ionis Pharmaceuticals, Inc.; Lilly; Medco Health Solutions, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
Served as a speaker or a member of a speakers bureau for: Algorithme Pharma inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Cipla Ltd.; Kowa Company Ltd.; Pfizer Inc; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Amgen Inc.; Pfizer Inc; Regeneron Pharmaceuticals, Inc.; Sanofi

Joyce L. Ross, MSN, CRNP, CS

Diplomate, Accreditation Council for Clinical Lipidology; Immediate Past President, National Lipid Association; Past President, Preventive Cardiovascular Nurses Association; Philadelphia, Pennsylvania

Disclosures

Disclosure: Joyce L. Ross, MSN, CRNP, CS, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Amarin Corporation plc; Amgen Inc.; Kaneka Americas Holding, Inc.; Kowa Company Ltd.; Regeneron Pharmaceuticals, Inc.; Sanofi
Special Instructions for EBAC programs or faculty from Johns Hopkins University or Emory University/Healthcare: Special disclosure language or disclaimer statements must be used (EBAC: place BEFORE authors; JHU and Emory place statement AFTER faculty affiliation and BEFORE disclosure information):

Editor

Joy P. Marko, MS, APN-C, CCMEP

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Joy P. Marko, MS, APN-C, CCMEP, has disclosed no relevant financial relationships.

CME Reviewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For Nurses

Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.5 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number JA0007105-0000-18-165-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Family Medicine

CME / ABIM MOC / CE

Obesity and Dyslipidemia: How Would You Treat?

Authors: Harold Bays MD; Chima Nwizu MD; Adina S. Gutstein, MSN, CRNP, CLSFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 8/20/2018

Valid for credit through: 8/20/2019, 11:59 PM EST

processing....

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator

Harold Bays, MD

Panelists

Chima Nwizu, MD

Adina S Gutstein, MSN, CRNP, CLS

Steering Committee

Chair

Alan S. Brown, MD

Members

Harold Bays, MD

Joseph L. Lillo, DO

Kevin C. Maki, PhD

Kausik Ray, MBChB, MD, MPhil (Cantab), FRCP (Lon), FRCP (Ed)

Joyce L. Ross, MSN, CRNP, CS

Editor

Joy P. Marko, MS, APN-C, CCMEP

CME Reviewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

CME / ABIM MOC / CE

Obesity and Dyslipidemia: How Would You Treat?

Target Audience and Goal Statement

Disclosures

Moderator

Harold Bays, MD

Panelists

Chima Nwizu, MD

Adina S Gutstein, MSN, CRNP, CLS

Steering Committee

Chair

Alan S. Brown, MD

Members

Harold Bays, MD

Joseph L. Lillo, DO

Kevin C. Maki, PhD

Kausik Ray, MBChB, MD, MPhil (Cantab), FRCP (Lon), FRCP (Ed)

Joyce L. Ross, MSN, CRNP, CS

Editor

Joy P. Marko, MS, APN-C, CCMEP

CME Reviewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Obesity and Dyslipidemia: How Would You Treat?